Replies to post #198918 on Avid Bioservices Inc (CDMO)

[BioBS2012]

MPDL3280A, anti-PDL1 immune checkpoint therapy, with a discussion of the usefulness of genetic markers, and a little about how RECIST criteria may not take into account long term responses to immunotherapy. (May require log-in)

www.medpagetoday.com/HematologyOncology/OtherCancers/48990

This is from the referenced article...

A third clinical research letter described patterns of immune-cell expression in response to treatment with the PD-1 receptor inhibitor pembrolizumab (Keytruda). Paul C. Tumeh, MD, of the University of California Los Angeles, and colleagues examined biopsy specimens obtained before and after treatment from patients with metastatic melanoma.

The results showed that pre-treatment levels of CD8+ T cells at the tumor margin correlated with expression of the PD-1/PD-L1 immune inhibition axis. Patients whose tumors responded to treatment had higher concentrations of CD8-, PD-1-, and PD-L1-expressing cells at the invasive tumor margin and intratumorally.

Now take a look at this PPHM liver biopsy poster

http://www.peregrineinc.com/images/stories/pdfs/sitc_2014_h_nk_pphm_1240.pdf